Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

  • Revenue in GBP (TTM)19.55bn
  • Net income in GBP2.82bn
  • Incorporated1992
  • Employees76.10k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
AZN:LSE since
Alexion Pharmaceuticals IncAnnounced12 Dec 202012 Dec 2020Announced2.21%39.31bn
Data delayed at least 20 minutes, as of Jun 11 2021 16:37 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lonza Group AG3.56bn576.16m38.89bn16.54k67.697.2140.1210.939.7711.6360.3491.740.3189----272,551.405.185.126.556.3540.9938.9516.2413.111.1814.440.342133.197.153.4612.8321.3929.815.31
GlaxoSmithKline plc32.43bn5.26bn70.61bn94.07k13.444.7511.,726.007.356.2111.5110.3867.5668.8418.4112.690.6079.040.5552113.091.027.3523.77-7.353.330.00
Sanofi SA31.70bn10.47bn96.20bn99.41k9.16--,574.90--4.98--5.9767.5868.1332.5514.73--29.88--69.80-0.69621.40323.6022.79-5.281.78
Novo Nordisk A/S14.64bn4.95bn105.73bn45.16k28.0720.0718.737.2218.4118.4154.4825.750.94811.194.372,836,907.0032.0335.3064.9167.1883.1784.1033.7833.510.5904--0.141750.324.043.308.183.8728.087.29
AstraZeneca plc19.55bn2.82bn110.01bn76.10k39.0910.7522.415.632.142.1414.887.790.45171.574.86256,953.206.483.889.635.4678.9780.9714.3410.190.6723.580.5822141.039.161.50139.402.50-1.340.2156
Data as of Jun 11 2021. Currency figures normalised to AstraZeneca PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.64%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202068.53m5.22%
Capital Research & Management Co. (World Investors)as of 31 Dec 202056.10m4.27%
BlackRock Investment Management (UK) Ltd.as of 31 Dec 202054.58m4.16%
The Vanguard Group, Inc.as of 01 Jun 202135.25m2.69%
Norges Bank Investment Managementas of 01 Jun 202130.24m2.30%
BlackRock Fund Advisorsas of 01 Jun 202124.89m1.90%
BlackRock Advisors (UK) Ltd.as of 01 Jun 202117.04m1.30%
SSgA Funds Management, Inc.as of 01 Jun 202113.58m1.04%
State Street Global Advisors Ltd.as of 01 Jun 202112.01m0.92%
BlackRock Advisors LLCas of 01 Jun 202111.22m0.85%
More ▼
Data from 31 Dec 2020 - 09 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.